Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction

September 1, 2011 By Bio-Medicine.Org

MOUNTAIN VIEW, Calif., Sept. 1, 2011 /PRNewswire/ — VIVUS,
Inc. (NASDAQ:
VVUS
) today announced that the U.S. Food and Drug
Administration (FDA) has accepted for review the company’s new drug
application (NDA) for its investigational drug candidate, avanafil,
for the treatment of erectile dysfunction (ED). The target date for
the FDA to complete its review of the avanafil NDA is April 29,
2012. In previously announced results from the pivotal phase 3
trials, patients treated with avanafil achieved significant
improvement in erectile function compared to placebo. The avanafil
development program included over 1,350 patients and avanafil was
shown to be well tolerated and effective in treating patients with
general ED and diabetics with ED. The long-term safety study also
confirmed the results observed in the phase 3 studies.

“We are pleased with FDA’s acceptance of our NDA. If approved,
avanafil could be a valuable treatment alternative for the 18
million men in the United States that suffer from ED,” stated Peter
Y. Tam, president of VIVUS.

About AvanafilAvanafil is an investigational oral medication
being developed for the treatment of erectile dysfunction.
 Avanafil is a highly selective phosphodiesterase type 5
(PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma
Corporation. VIVUS owns worldwide development and commercial rights
to avanafil for the treatment of sexual dysfunction, with the
exception of certain Asian Pacific Rim countries.

About VIVUS VIVUS is a biopharmaceutical company developing
therapies to address obesity, sleep apnea, diabetes and male sexual
health. The company’s lead investigational product in clinical
development, QNEXA®, has completed phase 3 clinical trials for
the treatment of obesity and is currently being considered for
approval by US and EU regulators. VIVUS received a Complete
Response Letter, or CRL,

‘/>”/>

SOURCE

Related Articles Read More >

An illustration of Embolization Inc.'s Nitinol Enhanced Device (NED).
This nitinol vascular embolization device has another shape memory material up its sleeve
July 2025 edition: The Surgical Robotics issue, featuring Capstan Medical, J&J and Zimmer Biomet
A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe